Roche claims midstage win for obesity injectable Roche reports weight loss of up to 22.5% with its injectable GIP/GLP-1 agonist obesity drug, setting up phase 3, but will it be too late to the table?

#weightloss #obesity #drugdevelopment #Roche #obesityinjectable #phase2results #dualGIPGLP1agonist #phase3programme #CT388 #CarmotTherapeutics #BMI #GLP1directedmedicines #EliLilly #GIPGLP1activity #NovoNordisk #GLP1drug #obesitycategory #IQVIA #ZealandPharma
zurl.co/nATCt

High dose of Wegovy drives weight loss to 19% A triple dose of Novo Nordisk's GLP-1 agonist Wegovy has shown improved activity on weight loss in an obesity trial versus the current formulation

#obesitymanagement #weighloss #obesity #Wegovy #ObesityActionCoalition #NovoNordisk #GLP1agonist #weightloss #obesitytrial #EliLilly #Lilly #TheLancetDiabetesandEndocrinology #STEPUPT2D #highdosesemaglutide #dualGIPGLP1agonist #Zepbound #tirzepatide #oralGLP1agonist
zurl.co/GCtWR